Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.
You may also be interested in...
Xarelto Approval For AF Stroke Risk Reduction Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed
J&J/Bayer’s Xarelto tested the limits of FDA’s policy on comparative efficacy, thanks to suboptimal use of the active comparator, warfarin, and the introduction of a new competitor, Pradaxa. In the medical reviewers’ view, new therapies should be as effective as existing therapies used skillfully, but division leadership would withhold approval only if the new drug were clearly inferior to approved agents.
Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.
Xarelto Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed
J&J/Bayer’s Xarelto tested the limits of FDA’s policy on comparative efficacy, thanks to suboptimal use of the active comparator, warfarin, and the introduction of a new competitor, Pradaxa. In the medical reviewers’ view, new therapies should be as effective as existing therapies used skillfully, but division leadership would withhold approval only if the new drug were clearly inferior to approved agents.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: